Suzano S.A. — 2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter earnings report; the provided filing text does not give clear Q4-only financial results. Financial statements are prepared under IFRS as issued by the IASB and reported in Brazilian reais (R$).
Business context
Suzano is a Brazilian, vertically integrated pulp and paper producer. Its two reportable segments are pulp and paper, with sales concentrated in export markets. Installed capacity was reported as 10.9 million tons of pulp and 1.5 million tons of paper in the operational data. The company also acquired Kimberly-Clark’s Brazilian tissue business in June 2023.
Key financial and operating metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | R$39.76bn | R$49.83bn |
| Gross profit / margin | R$14.68bn / 36.9% | R$25.01bn / 50.2% |
| Operating profit / margin | R$12.22bn / 30.7% | R$22.22bn / 44.6% |
| EBITDA (non-GAAP) / margin | R$19.54bn / 49.1% | R$29.63bn / 59.5% |
| Adjusted EBITDA (non-GAAP) | R$18.27bn | R$28.19bn |
| Net income | R$14.11bn | R$23.39bn |
| Cash provided by operating activities | R$17.32bn | R$21.64bn |
| Capital expenditures, cash basis | R$18.58bn | R$16.31bn |
| Cash and cash equivalents at year-end | R$8.35bn | R$9.51bn |
| Loans, financing and debentures | R$77.17bn | R$74.57bn |
| Working capital / current ratio | R$23.77bn / 2.6x | R$22.63bn / not stated |
Marketable securities totaled R$13.27bn at year-end 2023, making cash plus marketable securities approximately R$21.61bn. Simple operating cash flow less reported cash-basis capex was approximately negative R$1.26bn; this is an analyst calculation, not a company-reported free-cash-flow measure. The company also had US$1.275bn of undrawn revolving credit facilities available through February 2027.
Changes versus 2022
- Net sales fell 20.2%, primarily as pulp prices declined and pulp sales volume decreased 3.6%. Pulp revenue fell 25.9%; pulp sales volume was 10.22 million tons versus 10.60 million.
- Management reported the average pulp price in U.S. dollars was down 20.5% year over year. Pulp prices weakened during the second quarter amid destocking, higher inventories and new capacity, then recovered more noticeably in the fourth quarter.
- Paper revenue increased 7.5% to R$9.08bn, largely reflecting higher domestic prices and the tissue acquisition. Paper sales volume edged down to 1.29 million tons from 1.31 million.
- Gross profit declined 41.3% and net income declined 39.7%. Cost of sales was nearly flat, as lower commodity costs and sales volume were offset by wood costs, scheduled maintenance downtime, inflation and higher depreciation.
- Operating cash flow decreased R$4.33bn. Investing cash outflow rose to R$26.04bn, including R$11.67bn of property, plant and equipment additions, R$5.78bn of biological-asset additions and acquisition-related spending.
- Debt increased about 3.5% to R$77.17bn. The company reported R$61.30bn of debt denominated in U.S. dollars and R$15.87bn in Brazilian reais. Its reported net financial result remained positive at R$5.78bn, mainly reflecting derivative and currency results.
Outlook, commentary and items to monitor
- Cerrado Project: The new Ribas do Rio Pardo pulp mill has nominal capacity of 2.55 million tons annually. Total project investment was revised from R$19.3bn to R$22.2bn. At the filing date, operations were expected to start in the first half of 2024. Management estimated production cash cost, excluding scheduled maintenance stops, at about R$500 per ton after the learning curve and R$400 per ton from the second forest cycle.
- Investment plans: The approved 2024 capex budget was R$16.45bn; management separately announced R$7.68bn of maintenance capex. The filing says 2024 spending would be funded primarily through cash and cash generation, with capital-market or bank access available if needed.
- No broad earnings guidance: The filing text provides project and investment expectations but no clear formal revenue or earnings forecast.
- Non-GAAP and unusual items: EBITDA and Adjusted EBITDA are company-defined non-GAAP measures and should not be treated as substitutes for IFRS results. 2023 operating income included a R$1.99bn gain from the fair-value adjustment of biological assets, which is non-cash. Net financial results included R$5.53bn of derivative gains and R$3.09bn of net monetary and exchange gains; these items can be volatile.
- Acquisition: The Brazilian tissue business purchase consideration was R$1.06bn after a working-capital adjustment. The acquisition contributed to higher selling and administrative expenses; the filing does not provide a comparable standalone historical revenue or profit series for the acquired carve-out.
- Risks and contingencies: Key exposures include cyclical global pulp prices and demand, especially in China; exchange rates and foreign-currency debt; refinancing and interest-rate costs; wood supply, drought, fire and climate impacts; logistics and operating interruptions; environmental permits and regulation; and tax, land, labor and environmental disputes. Possible-loss proceedings totaled R$14.43bn at year-end (tax and social security R$9.78bn, civil/environmental R$4.46bn and labor R$0.19bn); these were not provisioned as possible losses. Provisions for judicial liabilities, net of deposits, were R$2.86bn.
- Audit and controls: PwC issued an unqualified audit opinion and concluded internal control over financial reporting was effective. Critical audit matters included biological-asset valuation, impairment testing of pulp-segment goodwill and tax/legal contingencies. Management reported no material cybersecurity incident in 2023.
- Management transition: After year-end, Suzano announced that CEO Walter Schalka would leave the role effective July 1, 2024, with João Alberto Fernandez de Abreu appointed as successor.
Important facts for investors to verify
- Check subsequent filings for the actual Cerrado start-up date, ramp-up, final project cost and achieved cash costs against the stated expectations.
- Review pulp-price, sales-volume and Chinese demand trends, and assess how the fourth-quarter price recovery carried into 2024.
- Reconcile debt, available liquidity, foreign-currency exposure, derivatives and upcoming maturities; distinguish cash from marketable securities and consider lease liabilities separately.
- Assess the sustainability and cash character of reported earnings, including biological-asset fair-value gains and derivative/currency results; compare IFRS profit with the company’s adjusted measures.
- Track the outcome of material tax, land, environmental and licensing matters, alongside the R$14.43bn possible-loss exposure and the assumptions used for provisions.
- Verify the realized 2024 capex, tissue-acquisition contribution and CEO transition, and review the progress of ESG-linked targets that may affect financing costs.